<p>美国金融公式在最近向证券交易委员会提交的 13F 文件中表示，在第三季度将其在雅培（NYSE:ABT - 免费报告）股票中的持股比例减少了 91.2%。该机构投资者在本季度出售了 10,060 股后，持有 971 股该医疗产品制造商的股票。美国金融公式在雅培的持股在最近的报告期末价值为 130,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>博通刚刚提高了其股息——但这并不是唯一一个显示出强劲信号的公司</li>
</ul>
<p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Avanza Fonder AB 在第二季度将其在雅培的持股比例提高了 0.4%。Avanza Fonder AB 现在拥有 168,401 股该医疗产品制造商的股票，价值 22,904,000 美元，此前在上个季度又购买了 655 股。查尔斯·施瓦布信托公司在第三季度将其在雅培的持股增加了 109.8%。查尔斯·施瓦布信托公司现在拥有 29,412 股该医疗产品制造商的股票，价值 3,939,000 美元，此前在该期间又收购了 15,394 股。Seaview Investment Managers LLC 在第二季度购买了雅培的新头寸，价值约为 11,068,000 美元。Guggenheim Capital LLC 在第二季度将其在雅培的持股提高了 13.5%。Guggenheim Capital LLC 现在拥有 98,941 股该医疗产品制造商的股票，价值 13,457,000 美元，此前在该期间又收购了 11,794 股。最后，Vest Financial LLC 在第二季度将其在雅培的持仓提高了 12.1%。Vest Financial LLC 现在拥有 592,300 股该医疗产品制造商的股票，价值 80,559,000 美元，此前在上个季度又购买了 63,811 股。目前 75.18% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>几家研究公司最近对 ABT 发布了报告。杰富瑞金融集团在 2023 年 10 月 16 日的研究报告中将雅培的目标股价从 145.00 美元提高至 149.00 美元，并给予该公司 “买入” 评级。威廉·布莱尔在 2023 年 11 月 20 日的研究报告中将雅培的股票评级提高至 “强力买入”。BTIG 研究在 2023 年 11 月 20 日的研究报告中重申了 “买入” 评级，并对雅培的股票设定了 145.00 美元的目标价。高盛集团在 2023 年 10 月 1 日的研究报告中将雅培的目标价从 153.00 美元提高至 157.00 美元，并给予该股票 “买入” 评级。最后，雷蒙德·詹姆斯金融在 2023 年 10 月 16 日的研究报告中将雅培的目标价从 141.00 美元提高至 146.00 美元，并给予该公司 “跑赢大盘” 评级。两位研究分析师对该股票给予了强力买入评级，十七位给予了买入评级，四位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 147.00 美元。</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底线</li>
</ul>
<p><strong>查看我们对雅培的最新分析</strong></p>
<h2>雅培股票表现</h2>
<p>NYSE:ABT 周一开盘价为 125.45 美元。该股票的 50 日移动平均线为 126.77 美元，200 日移动平均线为 130.23 美元。雅培的 12 个月低点为 110.86 美元，12 个月高点为 141.23 美元。该公司的市值为 2181.3 亿美元，市盈率为 15.72，市盈增长比率为 2.29，贝塔系数为 0.72。该公司的流动比率为 1.70，速动比率为 1.24，债务股本比率为 0.23。</p>
<ul>
<li>雅培在十月份的股价暴跌是买入信号</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）在 2023 年 10 月 15 日发布了其财报。该医疗产品制造商报告本季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司的季度收入为 113.7 亿美元，而市场共识预期为 114 亿美元。去年同期，该公司的每股收益为 1.21 美元。与去年同期相比，该公司的季度收入增长了 6.9%。雅培已将其 2025 财年的指导目标设定为每股收益 5.120-5.180 美元。分析师平均预计雅培在当前财年将发布每股收益 5.14 美元。</p>
<h2>雅培增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 2024 年 2 月 13 日支付。2024 年 1 月 15 日的股东将获得每股 0.63 美元的股息。该股息的除息日期为 2024 年 1 月 15 日。这比雅培之前的季度股息 0.59 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 2.0%。雅培的派息比率目前为 29.57%。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的阿博特公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，业务涵盖诊断、医疗设备、营养品和成熟药物等多个领域。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断领域，雅培提供实验室和现场检测平台及用于检测传染病、慢性病和生物标志物的检测方法；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比雅培更好的股票</li>
<li>美国结束更新</li>
<li>他们嘲笑 30 美元。他们不会嘲笑 70 美元。</li>
<li>我不应该把这个发给你</li>
<li>100 万美元在退休后能维持多久？</li>
<li>埃隆警告 “美国破产”。特朗普的计划在这里。</li>
</ul>
<p><strong>想看看其他对 ABT 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>美国金融公式在第三季度大幅减少了对雅培的持股，降幅达到 91.2%，目前持有 971 股，价值 13 万美元。其他机构投资者调整了他们的持仓，Avanza Fonder AB、查尔斯·施瓦布信托公司、Seaview Investment Managers LLC、Guggenheim Capital LLC 和 Vest Financial LLC 均增加了他们的持股。分析师对雅培给予了 “适度买入” 的评级，目标价共识为 147.00 美元。该公司报告第三季度每股收益为 1.30 美元，与预期相符，并宣布了季度分红</p>

<p>USA Financial Formulas decreased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 91.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 971 shares of the healthcare product maker's stock after selling 10,060 shares during the quarter. USA Financial Formulas' holdings in Abbott Laboratories were worth $130,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>美国金融公式在最近向证券交易委员会提交的 13F 文件中表示，在第三季度将其在雅培（NYSE:ABT - 免费报告）股票中的持股比例减少了 91.2%。该机构投资者在本季度出售了 10,060 股后，持有 971 股该医疗产品制造商的股票。美国金融公式在雅培的持股在最近的报告期末价值为 130,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength</li>
</ul>
<div class="lb-trans"><ul>
<li>博通刚刚提高了其股息——但这并不是唯一一个显示出强劲信号的公司</li>
</ul>
</div><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Avanza Fonder AB raised its stake in shares of Abbott Laboratories by 0.4% during the 2nd quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker's stock valued at $22,904,000 after buying an additional 655 shares during the last quarter. Charles Schwab Trust Co grew its holdings in Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker's stock worth $3,939,000 after acquiring an additional 15,394 shares during the period. Seaview Investment Managers LLC purchased a new position in Abbott Laboratories during the second quarter valued at approximately $11,068,000. Guggenheim Capital LLC lifted its holdings in Abbott Laboratories by 13.5% in the second quarter. Guggenheim Capital LLC now owns 98,941 shares of the healthcare product maker's stock valued at $13,457,000 after acquiring an additional 11,794 shares during the period. Finally, Vest Financial LLC boosted its position in Abbott Laboratories by 12.1% in the 2nd quarter. Vest Financial LLC now owns 592,300 shares of the healthcare product maker's stock worth $80,559,000 after purchasing an additional 63,811 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Avanza Fonder AB 在第二季度将其在雅培的持股比例提高了 0.4%。Avanza Fonder AB 现在拥有 168,401 股该医疗产品制造商的股票，价值 22,904,000 美元，此前在上个季度又购买了 655 股。查尔斯·施瓦布信托公司在第三季度将其在雅培的持股增加了 109.8%。查尔斯·施瓦布信托公司现在拥有 29,412 股该医疗产品制造商的股票，价值 3,939,000 美元，此前在该期间又收购了 15,394 股。Seaview Investment Managers LLC 在第二季度购买了雅培的新头寸，价值约为 11,068,000 美元。Guggenheim Capital LLC 在第二季度将其在雅培的持股提高了 13.5%。Guggenheim Capital LLC 现在拥有 98,941 股该医疗产品制造商的股票，价值 13,457,000 美元，此前在该期间又收购了 11,794 股。最后，Vest Financial LLC 在第二季度将其在雅培的持仓提高了 12.1%。Vest Financial LLC 现在拥有 592,300 股该医疗产品制造商的股票，价值 80,559,000 美元，此前在上个季度又购买了 63,811 股。目前 75.18% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research firms recently issued reports on ABT. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, October 16th. William Blair raised shares of Abbott Laboratories to a &#34;strong-buy&#34; rating in a research note on Thursday, November 20th. BTIG Research restated a &#34;buy&#34; rating and issued a $145.00 price target on shares of Abbott Laboratories in a research note on Thursday, November 20th. The Goldman Sachs Group increased their price target on Abbott Laboratories from $153.00 to $157.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, October 1st. Finally, Raymond James Financial boosted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $147.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 ABT 发布了报告。杰富瑞金融集团在 2023 年 10 月 16 日的研究报告中将雅培的目标股价从 145.00 美元提高至 149.00 美元，并给予该公司 “买入” 评级。威廉·布莱尔在 2023 年 11 月 20 日的研究报告中将雅培的股票评级提高至 “强力买入”。BTIG 研究在 2023 年 11 月 20 日的研究报告中重申了 “买入” 评级，并对雅培的股票设定了 145.00 美元的目标价。高盛集团在 2023 年 10 月 1 日的研究报告中将雅培的目标价从 153.00 美元提高至 157.00 美元，并给予该股票 “买入” 评级。最后，雷蒙德·詹姆斯金融在 2023 年 10 月 16 日的研究报告中将雅培的目标价从 141.00 美元提高至 146.00 美元，并给予该公司 “跑赢大盘” 评级。两位研究分析师对该股票给予了强力买入评级，十七位给予了买入评级，四位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 147.00 美元。</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底线</li>
</ul>
</div><p><strong>View Our Latest Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>查看我们对雅培的最新分析</strong></p>
</div><h2>Abbott Laboratories Price Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><p>NYSE:ABT opened at $125.45 on Monday. The stock has a 50 day moving average of $126.77 and a two-hundred day moving average of $130.23. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The firm has a market cap of $218.13 billion, a P/E ratio of 15.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.72. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23.</p>
<div class="lb-trans"><p>NYSE:ABT 周一开盘价为 125.45 美元。该股票的 50 日移动平均线为 126.77 美元，200 日移动平均线为 130.23 美元。雅培的 12 个月低点为 110.86 美元，12 个月高点为 141.23 美元。该公司的市值为 2181.3 亿美元，市盈率为 15.72，市盈增长比率为 2.29，贝塔系数为 0.72。该公司的流动比率为 1.70，速动比率为 1.24，债务股本比率为 0.23。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培在十月份的股价暴跌是买入信号</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter last year, the business posted $1.21 earnings per share. The business's quarterly revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）在 2023 年 10 月 15 日发布了其财报。该医疗产品制造商报告本季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司的季度收入为 113.7 亿美元，而市场共识预期为 114 亿美元。去年同期，该公司的每股收益为 1.21 美元。与去年同期相比，该公司的季度收入增长了 6.9%。雅培已将其 2025 财年的指导目标设定为每股收益 5.120-5.180 美元。分析师平均预计雅培在当前财年将发布每股收益 5.14 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. Abbott Laboratories's payout ratio is currently 29.57%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 2024 年 2 月 13 日支付。2024 年 1 月 15 日的股东将获得每股 0.63 美元的股息。该股息的除息日期为 2024 年 1 月 15 日。这比雅培之前的季度股息 0.59 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 2.0%。雅培的派息比率目前为 29.57%。</p>
</div><h2>Abbott Laboratories Company Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的阿博特公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，业务涵盖诊断、医疗设备、营养品和成熟药物等多个领域。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断领域，雅培提供实验室和现场检测平台及用于检测传染病、慢性病和生物标志物的检测方法；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>End of America update</li>
<li>They Laughed at $30. They Won’t Laugh at $70.</li>
<li>I Shouldn't Be Sending You This</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比雅培更好的股票</li>
<li>美国结束更新</li>
<li>他们嘲笑 30 美元。他们不会嘲笑 70 美元。</li>
<li>我不应该把这个发给你</li>
<li>100 万美元在退休后能维持多久？</li>
<li>埃隆警告 “美国破产”。特朗普的计划在这里。</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ABT 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

USA Financial Formulas 出售了雅培公司 $ABT 的股票